PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-0.34%
Negative net income growth while CRON.TO stands at 22.92%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
13.90%
D&A growth well above CRON.TO's 21.42%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
311.60%
Some yoy growth while CRON.TO is negative at -178105.17%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
107.88%
SBC growth while CRON.TO is negative at -66.12%. John Neff would see competitor possibly controlling share issuance more tightly.
-42.22%
Negative yoy working capital usage while CRON.TO is 46.82%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
-110.24%
Both yoy AR lines negative, with CRON.TO at -78.90%. Martin Whitman would suspect an overall sector lean approach or softer demand.
-90.14%
Both reduce yoy inventory, with CRON.TO at -198.97%. Martin Whitman would find a widespread caution or cyclical demand drop in the niche.
88.89%
AP growth well above CRON.TO's 96.86%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
224.56%
Growth well above CRON.TO's 68.68%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-38.45%
Negative yoy while CRON.TO is 100.74%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-73.67%
Negative yoy CFO while CRON.TO is 26.90%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-2.03%
Both yoy lines negative, with CRON.TO at -621.31%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-736193.53%
Both yoy lines negative, with CRON.TO at -3846.43%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
-100.00%
Both yoy lines negative, with CRON.TO at -242.14%. Martin Whitman would suspect an environment with fewer attractive securities or a strategic pivot to internal growth.
-90.37%
We reduce yoy sales while CRON.TO is 146.11%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-83.73%
We reduce yoy other investing while CRON.TO is 86.35%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-414.21%
Both yoy lines negative, with CRON.TO at -20.23%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
26.28%
Debt repayment above 1.5x CRON.TO's 11.29%, indicating stronger deleveraging. David Dodd would verify if expansions are not neglected.
100.00%
Issuance growth of 100.00% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.